The effect of empagliflozin on the development of chronic heart failure after myocardial infarction according to a 12-month prospective study
BACKGROUND: Although the positive cardiovascular effect of empagliflozin has been established, its influence on the formation of heart failure (HF) in patients with type 2 diabetes mellitus (T2D) after myocardial infarction (MI) remains unknown. AIM: To study the effect of empagliflozin on the form...
Guardado en:
Autores principales: | Alexey A. Nekrasov, Elena S. Timoschenko, Leonid G. Strongin, Tatyana A. Nekrasova, Anastasiya A. Baranova, Svetlana N. Botova, Michail V. Timoschenko, Mariya A. Yaroslavtseva |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/444a2d0105754863905b7b402497325b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
por: A. V. Simanenkova, et al.
Publicado: (2021) -
Empagliflozin: a new strategy for nephroprotection in diabetes
por: Anton Ivanovich Korbut, et al.
Publicado: (2017) -
Innate Lymphoid Cells and Myocardial Infarction
por: Wenling Yang, et al.
Publicado: (2021) -
IL-17A levels increase in the infarcted region of the left ventricle in a rat model of myocardial infarction
por: Ávalos,Ana María, et al.
Publicado: (2012) -
Diabetes mellitus type 2 and acute myocardial infarction: prognostic options for interaction in patients of different age groups
por: Alla A. Garganeeva, et al.
Publicado: (2018)